Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Deals

Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies

Fineline Cube Oct 18, 2023

Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...

Company

J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance

Fineline Cube Oct 18, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global...

Company Deals

Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection

Fineline Cube Oct 18, 2023

China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South...

Company Deals

Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology

Fineline Cube Oct 18, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced...

Company Drug

BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer

Fineline Cube Oct 18, 2023

BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...

Company Drug

Mabwell to Present Promising Clinical Data at 2023 ESMO Congress

Fineline Cube Oct 18, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...

Company Deals

Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development

Fineline Cube Oct 18, 2023

Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in...

Company Deals

SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group

Fineline Cube Oct 18, 2023

China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals...

Company Digital

Baidu Launches Interactive AI Medication Instructions Service at Baidu World 2023

Fineline Cube Oct 18, 2023

Robin Li, CEO of China-based internet services giant Baidu, unveiled an innovative interactive AI medication...

Company Deals

Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone

Fineline Cube Oct 17, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at...

Company Deals

Ascentage Pharma and AstraZeneca Expand Collaboration on CLL/SLL Treatment

Fineline Cube Oct 17, 2023

China’s Ascentage Pharma (HKG: 6855) and UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) have entered...

Company Drug

Asieris Pharma Launches Generic Votrient for Renal Cell Carcinoma in China

Fineline Cube Oct 17, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd, trading as Asieris Pharma (SHA: 688176),...

Company Drug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for Follicular Lymphoma Treatment

Fineline Cube Oct 17, 2023

China-based biotechnology leader BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the receipt of...

Company Deals

EpimAb Biotherapeutics Licenses Bispecific Antibody Platform to Almirall

Fineline Cube Oct 17, 2023

Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall...

Company Deals

MSD Partners with Phanes Therapeutics for Innovative Cancer Combo Therapy

Fineline Cube Oct 17, 2023

Global pharmaceutical leader Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic partnership...

Company Deals

Jiangsu Hengrui Licenses Camrelizumab-Apatinib Combo to Elevar Therapeutics

Fineline Cube Oct 17, 2023

China-based pharmaceutical giant Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has signed a significant licensing...

Company Drug

Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study

Fineline Cube Oct 17, 2023

Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...

Company Drug

Simcere’s SIM0237 Receives NMPA Approval for Bladder Cancer Trial

Fineline Cube Oct 17, 2023

China-based pharmaceutical innovator Simcere Pharmaceutical Group (HKG: 2096) has announced the receipt of an additional...

Company Drug

Abbisko Therapeutics to Unveil Phase I Data for ABSK011 and ABSK043 at ESMO 2023

Fineline Cube Oct 17, 2023

Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results...

Company Medical Device

MicroPort CardioFlow Medtech’s Third-Generation TAVI Product Achieves Initial Clinical Success

Fineline Cube Oct 17, 2023

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...

Posts pagination

1 … 511 512 513 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.